A medicinal product is defined as a substance that is either:
presented as preventing or treating disease, or
used to correct or modify a physiological function by pharmacological, immunological or metabolic action, or to make a medical diagnosis
It is often obvious whether a product should be classified as a medicinal product, medical device, cosmetic product, food, or a biocide. On the other hand, the regulatory status of so-called ‘borderline products’ is not immediately clear. The regulatory classification of a product can have important ramifications, for example, on how the product is regulated (and by whom), how long it will take before such product can be commercialised (especially if pre-market approval is required), how the product can be marketed and what advertising claims can be made etc. For an analysis of the definition of medicinal product and the borderline between medicinal products and other products, see Practice Note: Introduction to borderline products.
The borderline between cosmetic products and those that are regulated as a medicinal product or medical device or have health claims made when promoting them...
To view the latest version of this document and thousands of others like it, sign-in with LexisNexis or register for a free trial.
**Trials are provided to all LexisNexis content, excluding Practice Compliance, Practice Management and Risk and Compliance, subscription packages are tailored to your specific needs. To discuss trialling these LexisNexis services please email customer service via our online form. Free trials are only available to individuals based in the UK, Ireland and selected UK overseas territories and Caribbean countries. We may terminate this trial at any time or decide not to give a trial, for any reason. Trial includes one question to LexisAsk during the length of the trial.
This week’s edition of Life Sciences weekly highlights includes the key Autumn Budget 2026 announcements for the life sciences sector, covering new...
The Department of Health and Social Care (DHSC) has announced new UK-wide restrictions banning sales of nicotine-free vapes and nicotine products,...
In the Autumn Budget 2026, delivered on 28 October 2026, the Chancellor of the Exchequer, John Healey MP, announced plans for new regulatory powers...
The European Commission’s Directorate-General for Environment has summarised a 2025 report on environmental protection in EU pharmaceutical reform....
Priority between loss reliefs in loss making companiesWhy does it matter?A company that is a member of a group and has incurred any of the types of losses available for surrender by way of group relief may, without any further rules, have more than one way in which to use the loss. There are a
Late payment penalties—inheritance taxWhile interest often accrues on overdue tax, the late payment of certain taxes may also attract a penalty. For information on the interest accruing on overdue tax, see Practice Notes: IHT—payment deadlines on death—Interest on IHT and Interest on late paid
If a beneficiary signs a deed of disclaimer of their share of an estate and the estate pays their legal fees, will that count as a PET against their estate?A disclaimer is the refusal of a gift prior to acceptance. The refusal of the gift must take place before the beneficiary accepts any benefit
Can shares in a limited company that have not been paid-up at all be cancelled?A limited company having a share capital may not alter that share capital, except in the ways listed in section 617 of the Companies Act 2006 (CA 2006). Shares in a company cannot simply be cancelled without following an
0330 161 1234